Oncorus raises £65.5m funding to advance oncolytic virus therapies

This article was originally published here

Oncorus, which is headquartered in Cambridge, Massachusetts, is an oncolytic virus company. It is engaged in advancing a portfolio of locally and systemically administered (IV) OV therapies based

The post Oncorus raises £65.5m funding to advance oncolytic virus therapies appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply